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Available online xxxxBackground: Chronic kidney disease (CKD) is highly prevalent in atrial fibrillation (AF) patients and associated
with an increased risk of adverse outcomes. Our objectives were to study clinical features associated with CKD
in AF patients and the impact of CKD on anticoagulation control, as reflected by time in therapeutic range
(TTR). We also determined the impact of CKD and TTR in predicting adverse outcomes.
Methods and Results:We analysed pooled datasets from SPORTIF III and V trials, including 3646 patients assigned
to warfarin with data on renal function. CKD (creatinine clearance b60 ml/min) was present in 952 (26%)
patients. TTR was higher in patients with normal renal function compared to those with CKD (p b 0.001).
On logistic analysis, chronic AF andmale sexwere associatedwith TTR N 70%,whilst diabetesmellitus, aspirin use
and CKDwere inversely associatedwith TTR N 70%. On Cox regression analysis, CKDwas an independent predic-
tor for stroke (p= 0.006) and death (p b 0.001). TTR N 70% was independently associated with a lower risk of
stroke (p= 0.024), death (p= 0.001) and major bleeding (p= 0.001).
Conclusions: CKD is highly prevalent amongst AF patients and a risk factor for stroke and death. Adjusting for
CKD, good quality anticoagulation control (TTR N 70%) was an independent predictor for lower risks of
stroke, death and major bleeding.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Non-valvular atrial fibrillation
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Clinical outcomes1. Introduction
Chronic kidney disease (CKD) is highly prevalent in non-valvular AF
patients, ranging from 26% to 32%, especially in the elderly (Apostolakis
et al., 2013; Banerjee et al., 2013). The presence of CKD in AF patients is
associated with a greater risk of adverse clinical outcomes, including
stroke, thromboembolism and bleeding. In the Danish nationwide co-
hort study, for example, the presence of CKD amongst patients with
AFwas significantly associatedwith an increased risk for stroke/system-
ic embolism (by 1.49-fold), all-cause mortality (by 2.37-fold), myocar-
dial infarction (by 2-fold) and major bleeding (by 1.33-fold) (Olesen
et al., 2012). Warfarin use amongst such patients has been associated
with a substantial risk reduction in overall event rates, with a positive
net clinical benefit (Bonde et al., 2014). Similarly, the Loire Valley Atrial
Fibrillation Project confirmed the high risk associated with CKD in pa-
tients with AF (Banerjee et al., 2014, 2013). In clinical trial populations,
CKD also confers a much higher relative risk for both stroke and bleed-
ing (Apostolakis et al., 2013; Piccini et al., 2013).m Institute of Cardiovascular
m, United Kingdom.
. This is an open access article under
hronic Kidney Disease, Time i
icine (2016), http://dx.doi.orgWhen Vitamin K Antagonists (VKAs, e.g. warfarin) are used for
thromboprophylaxis, good quality anticoagulation control, as reflected
by time in therapeutic range (TTR) N70% is recommended (De
Caterina et al., 2013). Limited information been reported on the rela-
tionship betweenCKD and TTR in AFpatients, but good TTR has been as-
sociated with lower risks of thromboembolism and bleeding (Connolly
et al., 2008; Friberg et al., 2014; Pokorney et al., 2015).
In this study, our objectiveswere to study clinical features associated
with CKD in AF patients; second, we studied the impact of CKD on
anticoagulation control, as reflected by the time in therapeutic range
(TTR). Third, we determined the impact of CKD as a risk factor for
stroke, myocardial infarction, major bleeding and death amongst
warfarin-treated AF patients, after adjustment for TTR as measure of
anticoagulation control.
2. Methods
For the present analysis, we used the pooled study populations of
the Stroke Prevention using an Oral Thrombin Inhibitor in patients
with atrial Fibrillation (SPORTIF) III and V trials. The original protocol
and principal results have been previously described (Albers et al.,
2005; Halperin, 2003; Olsson, 2003). In brief, the SPORTIF trials werethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of the direct thrombin inhibitor, ximelagatran, against warfarin in pa-
tients with non-valvular AF. SPORTIF III was an open label trial, while
SPORTIF V was a double blind study (Halperin, 2003). Signed, informed
consent was required from each participant in accordance with protocol
regulations approved by the local review boards governing research in-
volving human subjects, and the Declaration of Helsinki. In both
SPORTIF trials, ximelagatran was non-inferior in efficacy and safety as
warfarin for stroke prevention in non-valvular AF patients (Lip, 2005)
but due to hepatotoxicity, ximelagatran was withdrawn. For the purpose
of this study,we studied only SPORTIF patients assigned towarfarin treat-
ment where complete information on renal function was available.
2.1. Thromboembolic Risk and Anticoagulation Control
Thromboembolic risk was categorised according to both CHADS2
and CHA2DS2-VASc scores (Gage et al., 2004; Lip et al., 2010). Based
on CHADS2, patients were categorised as “low risk” when with
CHADS2 = 0, “moderate risk” with CHADS2 = 1 and “high risk” when
CHADS2 ≥ 2 (Gage et al., 2004). Based on the CHA2DS2-VASc score,
“low risk” was defined as a CHA2DS2-VASc 0 in males or 1 in females;
“moderate risk” as male patients with CHA2DS2-VASc = 1; and “high
risk” with CHA2DS2-VASc ≥ 2 (Camm et al., 2012; Lip et al., 2015).
Anticoagulation control, as reflected by the TTRwas calculated using
the standardized Rosendaal interpolation method (Rosendaal et al.,
1993), by assigning an INR value to each day between two successive
observed INR values. The percentage of time that the interpolated INR
remained between 2.0 and 3.0 was used to establish TTR value, and
the cut-off value for defining optimal anticoagulation was a mean
individual TTR of ≥70% (De Caterina et al., 2013).
2.2. Renal Function
Renal functionwas based on the estimated creatinine clearance (CrCl),
using the 4-item Cockroft-Gault formula [(140 − age) ∗ (weight
in kg) ∗ (0.85 if female) / (72 ∗ creatinine)]. Accordingly, an estimated
CrCl level of b60 ml/min was used to define CKD, based on established
guidelines (“K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classification, and stratification.,” 2002).
2.3. Study Outcomes
Principal clinical outcomes were based on the original study proto-
col, and were centrally adjudicated (Halperin, 2003). Stroke was de-
fined as the acute onset of a focal neurological deficit in any of the
carotid, vertebral or cerebral artery distribution territories lasting
N24 h. As per the SPORTIF trials protocol, myocardial infarction (MI) di-
agnosis required 2 out of 3 of the following criteria: (i) typical chest pain
lasting at least 20min; (ii) electrocardiographic changes clearly indicat-
ing an acuteMI; (iii) significant, i.e. N2×upper limit, elevation of cardiac
biomarkers (creatine kinase-MB, troponin). Based on the International
Society of Thrombosis and Haemostasis (ISTH) criteria (Schulman and
Kearon, 2005), major bleeding was defined by one of the following:
clinically overt bleeding with a concomitant fall in haemoglobin levels
N2 g/dl or requiring blood transfusion of at least 2 units of whole
blood or erythrocytes; bleeding episode involving a critical site.
2.4. Statistical Analysis
All continuous variables were tested for normality with the Shapiro-
Wilk test. Variables with normal distribution were expressed as means
and standard deviations (SD), and tested for differences using a t-test.
Non-parametric variables were expressed as median and interquartile
range (IQR) and differences tested using the Mann-Whitney U test.
Categorical variables, expressed as counts and percentages, were
analysed by chi-squared test. A linear regression analysis betweenPlease cite this article as: Proietti, M., et al., Chronic Kidney Disease, Time i
Patients with Non-valvular Atria..., EBioMedicine (2016), http://dx.doi.orgCrCl and TTR was performed, adjusted for type of AF and thromboem-
bolic risk.
Regression analysis was performed in order to establish clinical
factors significantly associated with the presence of CKD. All vari-
ables different between the two groups at the baseline with a
level of significance of at least p b 0.10 underwent a univariate
analysis, and those predictors with a level significance of p b 0.10
were inserted into a forward multivariate logistic model. To deter-
mine the factors associated with a TTR N 70%, both for general pop-
ulation and CKD-only population, all baseline clinical variables
underwent univariate analyses and those predictors with a level
significance of p b 0.10 were inserted into a forward multivariate
logistic model. In order to explore the incremental value of TTR in
determining events occurrence, a correlation analysis between
TTR and hazard risk for study outcomes was performed using Pear-
son product-moment correlation test, both for the overall cohort
and stratified according to CKD presence. Correlation coefficients
were then compared using the z test, after being processed with
Fisher transformation.
Survival analysis, assessed by an intention-to-treat approach, was
performed according to the presence of CKD and differences in survival
distributors between subgroups were analysed using the Log-Rank test.
Evaluation of the clinical characteristics significantly associated with
outcomes was performed using a Cox proportional hazards analysis,
corrected according to thromboembolic risk, performed with CKD
both as a categorical variable and CrCl as a continuous variable. All de-
mographic variables, comorbidities and risk factors analysed at baseline
underwent a univariate analysis. All variables with a p-value b 0.10 for
the association with clinical outcome at the univariate analysis, were
inserted into the forward stepwise multivariate model. A backward
model was then performed to verify the results of the forward one. A
two-sided p value b 0.05 was considered statistically significant. All
analyses were performed using SPSS v. 22.0 (IBM, NY, USA) and R v.
3.2.1 (The R Foundation).
3. Results
The pooled study population constituted 7329 patients, of which
3665 were assigned to the warfarin treatment arm. Complete data on
renal function were available for 3646 (99.5%) [Fig. 1]. Of the selected
cohort, 30.5% (n = 1113) were female, median age was 72 [IQR 66–
77] years, andmedian CrClwas 78.60 [59.1–102.1]ml/min. Of the entire
cohort, 10.8% (n= 393) had paroxysmal AF.
3.1. Prevalence of CKD and Associated Clinical Characteristics
CKD (defined as CrCl b 60 ml/min) was present in 952 (26.1%)
patients. Clinical characteristics of patients with and without CKD
are shown in Table 1. Patients with CKD were significantly older
(p b 0.001), more commonly female (p b 0.001) or paroxysmal AF
(p = 0.009) and a lower median weight (p b 0.001). CKD patients
had more prevalent coronary heart disease (CHD) (p = 0.042) and
previous stroke or transient ischemic attack (TIA) (p b 0.001).
Thromboembolic risk was higher in patients with CKD compared to
those with normal renal function, whether based on CHADS2
(median [IQR] 2 [2–2] vs. 2 [1–2] respectively, p b 0.001) and
CHA2DS2-VASc (median [IQR] 4 [3–5] vs. 3 [2–3], p b 0.001).
On multivariable logistic regression analysis, clinical characteristics
significantly associated with the presence of CKD were age (Odds
Ratio (OR) 1.16 per year, 95% confidence interval (CI) 1.15–1.18,
p b 0.001), weight (OR for any kg 0.92, 95% CI 0.91–0.92, p b 0.001), par-
oxysmal AF (OR 1.67, 95% CI 1.23–2.27, p = 0.001), diabetes mellitus
(OR 1.47, 95% CI 1.16–1.86, p = 0.001), chronic heart failure (CHF)
(OR 1.61, 95% CI 1.32–1.96, p b 0.001), and previous stroke/TIA (OR
1.41, 95% CI 1.13–1.75, p= 0.002).n Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated
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Fig. 1. Patients included in this analysis.
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Median TTR in the whole cohort was 68.6% [IQR 56.5–80.6%], being
significantly higher in patients with normal renal function when
compared with CKD patients (p b 0.001). Also, the proportion with
TTR N 70% was more prevalent in patients with normal renal function
(p b 0.001).
After adjustment for type of AF and thromboembolic risk, a linear re-
lationship was found between CrCl and TTR (standardized beta: 0.054,
p = 0.003) [Fig. 2]. On multivariable logistic analysis, the presence of
chronic AF (OR 1.56, 95% CI 1.25–1.94, p b 0.001) and male sex (OR
1.18, 95% CI 1.01–1.35, p = 0.033) were positively associated with a
TTR N 70%. Conversely, a previous diagnosis of diabetes mellitus (OR
0.82, 95% CI 0.70–0.96, p = 0.011), concomitant use of aspirin (OR
0.75, 95% CI 0.63–0.88, p b 0.001) and the presence of CKD (OR 0.75,
95% CI 0.67–0.92, p=0.002) were negatively associated with achieving
a TTR N 70%.
In the CKD subgroup (n= 952), the weight (OR per kg 1.01, 95% CI
1.00–1.02, p= 0.041), the presence of CHF (OR 1.38, 95% CI 1.05–1.81,
p = 0.022) and chronic AF (OR 1.85, 95% CI 1.22–2.81, p = 0.004)
were significantly associated with TTR N 70%.3.3. Impact of CKD in Predicting Adverse Clinical Outcomes
After a median [IQR] follow-up time of 1.6 [1.3–1.8] years, 504
events (13.8% of patients) were recorded, as follows: 90 strokes
(17.9% of total events), 52 myocardial infarctions (10.3%), 198 deaths
(39.3%) and 164 major bleeding events (32.5%).3.3.1. Stroke
Strokewasmore common in CKDpatients than in patientswith nor-
mal renal function (2.6% patient-years vs. 1.3% patient-years, respec-
tively), with the unadjusted hazard ratio (HR) for stroke being 1.99
(95% CI: 1.30–3.03, p = 0.001). With CrCl as a continuous variable,Please cite this article as: Proietti, M., et al., Chronic Kidney Disease, Time i
Patients with Non-valvular Atria..., EBioMedicine (2016), http://dx.doi.orgevery decrease of 10ml/min was associated with a higher risk of stroke
(HR 1.07, 95% CI 1.00–1.14, p= 0.048).
On Kaplan-Meier analysis, CKD patients had a higher risk of
stroke compared to patients with normal renal function (Log-Rank
test: 10.56; p=0.001) [Fig. 3, Panel A]. On multivariable Cox regres-
sion analysis, a clinical history of CHD (p=0.045), a previous stroke/
TIA (p b 0.001) and the presence of CKD (p = 0.006) were indepen-
dent risk factors associated with the occurrence of stroke, while
TTR N 70% (p = 0.004) was inversely associated with the risk of
stroke (Table 2). Cox regression analysis performed using CrCl as a
continuous variable (Table 2) shows that its influence in determining
stroke risk became non-significant, after adjusting for other clinical
risk factors (p= 0.337). A backward selection model also confirmed
these results. TTR and HR for occurrence of stroke were inversely
correlated (r=−0.772, p b 0.001). Similarly, there was a significant
correlation between TTRs and stroke HRs according to renal function
subgroups [Fig. 4, Panel A] (r=−0.569, p b 0.001). A significant dif-
ference when comparing the two correlation coefficients for the
overall cohort and stratified according to CKD presence, respectively
(z = 8.61, p b 0.001).
3.3.2. Myocardial Infarction
The crude incidence rate of MI was similar between those with CKD
and normal renal function (1.1% and 0.9% patient-years, respectively).
No significant association was found between CKD and MI (unadjusted
HR 1.19, 95% CI 0.66–2.18, p= 0.563).
3.3.3. Major Bleeding
Major bleeding was more common in patients with CKD than in
those with normal renal function (4.6% patient-years, vs. 2.8% patient-
years, respectively). Similar to stroke, patients with CKD had a signifi-
cantly higher risk of a major bleeding event, compared to those with
normal renal function (Log-Rank: 10.03; p= 0.002) [Fig. 3, Panel B].
CKD conferred a higher risk of major bleeding (unadjusted HR 1.67,
95% CI 1.21–2.31, p = 0.002). This risk was non-significant when CrCl
was considered as a continuous variable (per decrease of 10 ml/min,
HR 1.04, 95% CI 0.99–1.09, p = 0.093). On multivariable analysis (see
Table 2), increasing age (p = 0.009) and clinical history of CHF (p =
0.036) were risk factors for major bleeding; conversely, TTR N 70%
(p=0.007)was independently associatedwith lessmajor bleeding. En-
tering CrCl in the analysis as a continuous variable did not affect the
multivariable model (Table 2). Similar data were obtained when
performing a backward selection model.
When correlating TTR and HR for major bleeding, a significant in-
verse relationship was found in the overall cohort (r = −0.527,
p b 0.001). When performed with HR according to renal function sub-
groups [Fig. 4, Panel B], there was a numerical reduction in correlation
coefficient (r =−0.490, p b 0.001), but this was non-significant (z =
1.57, p= 0.116).
3.3.4. All-cause Death
A higher rate of death was found in patients with CKD compared to
those with normal renal function (crude incidence rate 6.4% patient-
years vs. 2.5% patient-years; unadjusted HR 2.54 (95% CI 1.92–3.36,
p b 0.001)). As for stroke, a decrease of 10ml/min in CrCl was found as-
sociated with a higher risk of death (HR 1.14, 95% CI 1.08–1.20,
p b 0.001).
Survival analysis confirmed a higher mortality of patients with CKD
compared to patients with normal renal function (Log-Rank test: 45.62;
p b 0.001) [Fig. 3, Panel C]. Multivariable Cox regression analysis
(Table 2) shows that female sex (p = 0.013) and TTR N 70% (p =
0.002) were independently associated with a lower risk of death; con-
versely, a clinical history of CHF (p= 0.004), CHD (p b 0.001), smoking
habit (p=0.049) and the presence of CKD (p b 0.001) were risk factors
associated with an increased risk of death. When the Cox multivariable
analysis was performed using CrCl as a continuous variable, a decreasen Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated
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Table 1
Patient characteristics in relation to baseline renal function.
N (%) Normal renal function (≥60 ml/min)
N= 2694
Chronic kidney disease (b60 ml/min)
N= 952
p
Age, years (median [IQR]) 70 [64–75] 78 [74–82] b0.001
Weight, kg (median [IQR]) 89 [78–100] 70 [61–79] b0.001
Female 656 (24.4) 457 (48.0) b0.001
Creatinine clearance, ml/min 88.86 [74.02–111.57] 49.77 [43.01–55.25] b0.001
Type of atrial fibrillation (n= 3644) 0.009
Paroxysmal 269 (10.0) 124 (13.0)
Chronic 2424 (90.0) 827 (87.0)
Heart rate (n= 3510), per min 76 [67–87] 73 [64–86] b0.001
Hypertension 2082 (77.3) 717 (75.3) 0.216
Diabetes mellitus 652 (24.2) 205 (21.5) 0.095
Current smoker 272 (10.1) 58 (6.1) b0.001
Coronary heart disease 1162 (43.2) 447 (46.9) 0.042
Chronic heart failure 988 (36.7) 378 (39.7) 0.097
Previous stroke/TIA 485 (18.0) 263 (27.6) b0.001
Previous bleeding 154 (5.7) 54 (5.7) 0.958
Aspirin use 518 (19.2) 205 (21.6) 0.119
TTR (n= 3606), % (median [IQR]) 69.6 [56.7–80.2] 66.6 [51.9–76.8] b0.001
TTR N 70% (n= 3606) 1307 (48.9) 390 (41.8) b0.001
Median [IQR] CHADS2 2 [1–2] 2 [2–2] b0.001
CHADS2 score
0 99 (3.7) 13 (1.4)
1 1233 (45.8) 196 (20.6) b0.001
≥2 1362 (50.6) 743 (78.0)
Median [IQR] CHA2DS2-VASc 3 [2–3] 4 [3–5] b0.001
CHA2DS2-VASC risk class b0.001
Low risk 8 (0.3) 1 (0.1)
Intermediate risk 457 (17.0) 19 (2.0)
High risk 2229 (82.7) 932 (97.9)
Legend: BPM=beats perminute; IQR= interquartile range; TIA= transient ischemic attack; TTR= time in therapeutic range. Low risk=male patients with CHA2DS2-VASC 0 or female
patients with CHA2DS2-VASC 1; intermediate risk = male patients with CHA2DS2-VASC 1; high risk = all patients with CHA2DS2-VASC ≥ 2.
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difference was found when backward selection model was performed.
Similar to stroke, there was significant inverse correlation between
unadjusted HR for death and TTR (r = −0.676, p b 0.001), but the
correlation coefficient was reduced (r = −0.478, p b 0.001) when
stratifying according to CKD presence [Fig. 4, Panel C]. The difference
between correlation coefficients was significant (z = 8.40, p b 0.001).Fig. 2. Scatterplot and regression line between creatinine clea
Please cite this article as: Proietti, M., et al., Chronic Kidney Disease, Time i
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In this study,we demonstrate thatmore than a quarter of AF patients
have CKD, and that age, female sex, CHF, previous stroke/TIA and the oc-
currence of paroxysmal AFwere significantly associated with CKD in AF
patients. Second, we found a linear association between CrCl and TTR in
AF, and those patients with CKD had poorer anticoagulation control, asrance and TTR Legend = TTR: time in therapeutic range.
n Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated
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Fig. 3. Cumulative event-free survival in patients according to the presence of chronic
kidney disease. Panel A) Stroke p = 0.001; Panel B) Major bleeding p = 0.002; Panel
C) Death p b 0.001. Legend = Solid line: normal renal function; dashed line: CKD.
Table 2
Multivariable Cox regression analysis for clinical outcomes performedwith chronic kidney
disease as a categorical variable or creatinine clearance as a continuous variable.
Multivariable analysis
Hazard
ratio
95% CI p
Categorical variable
Stroke
TTR N 70% 0.63 0.41–0.98 0.040
Coronary heart disease 1.54 1.01–2.34 0.042
Chronic kidney diseasea 1.82 1.19–2.80 0.006
Previous stroke/TIA 2.23 1.44–3.44 b0.001
Major bleeding
TTR N 70% 0.58 0.42–0.80 0.001
Age (per year) 1.03 1.01–1.05 0.009
Chronic heart failure 1.40 1.02–1.92 0.036
Death
TTR N 70% 0.63 0.47–0.84 0.002
Female 0.66 0.47–0.92 0.013
Chronic heart failure 1.53 1.14–2.04 0.003
Current smoker 1.54 1.00–2.38 0.049
Coronary heart disease 1.77 1.32–2.37 b0.001
Chronic kidney diseasea 2.58 1.92–3.46 b0.001
Continuous variable
Stroke
TTR N 70% 0.60 0.39–0.93 0.024
Coronary heart disease 1.54 1.01–2.34 0.045
Previous stroke/TIA 2.18 1.40–3.38 0.001
Major bleeding
TTR N 70% 0.58 0.42–0.80 0.001
Age (per year) 1.03 1.01–1.05 0.009
Chronic heart failure 1.40 1.02–1.92 0.036
Death
TTR N 70% 0.61 0.46–0.82 0.001
Female 0.69 0.49–0.96 0.029
Current smoker 1.55 1.00–2.38 0.047
Chronic heart failure 1.58 1.19–2.12 0.002
Coronary heart disease 1.75 1.30–2.35 b0.001
Creatinine clearance (per 10 ml/min
decrease)
1.13 1.07–1.19 b0.001
Legend: CI = confidence interval; TIA = transient ischemic attack; TTR = time in
therapeutic range.
a Creatinine clearance b60 ml/min.
5M. Proietti et al. / EBioMedicine xxx (2016) xxx–xxxshown by a lower TTR when compared to patients with normal renal
function. Importantly, the presence of CKDwas negatively associated
with achieving a TTR N 70%. Third, CKD was an independent risk fac-
tor for the occurrence of stroke and death, independently from TTR;
however, no significant association was found between CKD andPlease cite this article as: Proietti, M., et al., Chronic Kidney Disease, Time i
Patients with Non-valvular Atria..., EBioMedicine (2016), http://dx.doi.orgboth myocardial infarction or major bleeding after adjusting for
TTR. Conversely, adequate anticoagulation control as expressed by
TTR N 70% was inversely associated with major bleeding.
Clinical factors associated with CKD have been previously reported
in a smaller real-world’ populations of AF patients and our data are
broadly confirmatory of the role of age, diabetes mellitus and CHF in
predicting the presence of CKD in AF patients (Roldán et al., 2013). In-
deed, both increasing age and diabetes mellitus are major predictors
of CKD in the general population (Fox, 2004). Conversely, hypertension
(an important risk factor for CKD in general population (Fox, 2004)) had
no significant influence on CKD amongst AF patients in our trial cohort.
CKD is predictive of stroke in AF patients, whilst oral anticoagulation
with VKA lowers stroke risk albeit at a higher risk of bleeding (Hart
et al., 2011). The Loire Valley Atrial Fibrillation Project showed that
CKD, defined as an estimated glomerular filtration rate (eGFR) below
60 ml/min/1.73 m2, was associated with a higher incidence of ischemic
stroke/thromboembolism events, but multivariable Cox regression
analysis did not demonstrate an independent effect of renal impairment
on predicting major adverse events, after adjusting for CHA2DS2-VASc
score risk factors (Banerjee et al., 2014, 2013).
Our results demonstrate that even in AF patients treated with warfa-
rin, CKD was still associated with a higher incidence of stroke, indepen-
dent of other concomitant risk factors. These data support previous
findings from another prospective randomised trial, where the presence
of a CrCl b60 ml/min was associated with two-fold higher risk of stroke
comparedwith thosewith CrCl ≥60ml/min (Apostolakis et al., 2013). Im-
portantly, we show that the predictive ability of CKD in identifyingn Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated
/10.1016/j.ebiom.2016.04.013
Fig. 4. Correlation between TTR and hazard risk according to presence of chronic kidney disease. Panel A) Stroke p b 0.001; Panel B) Major bleeding p b 0.001; Panel C) Death p b 0.001.
Legend = Cross and solid line: normal renal function; square and dashed line: CKD.
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7M. Proietti et al. / EBioMedicine xxx (2016) xxx–xxxpatients with a greater risk of stroke was independent of anticoagulation
control, as reflected by the TTR, notwithstanding the latter being a strong
predictor of adverse outcomes in patients with AF (White et al., 2007).
The lack of significant association between CrCl when analysed as a
continuous variable, and the risk of stroke could be attributed to more
complex and multifactorial physiological alterations present in patients
with established CKD that statistical adjustments would not be able to
fully adjust for. Indeed, the risk of cardiovascular disease is non-linear
in the transition from one functional CKD class to another, but increases
exponentially with greater impairment of renal function (Schiffrin et al.,
2007).
Our study also supports previous evidence showing that CKD is asso-
ciated with a higher risk for major bleeding (Apostolakis et al., 2013;
Banerjee et al., 2014), even when stratified according to VKA treatment
(Banerjee et al., 2014). Nonetheless, major bleeding is strongly related
to the quality of anticoagulation control, and supra-therapeutic INR
values amongst CKD patients are associated with a higher risk of devel-
oping a major bleed especially with progressive renal impairment
(Limdi et al., 2015). In contrast to other previous studies (Olesen et al.,
2012), we failed to show a significant association with MI risk, but
given the lownumber ofMIs recorded, this lack of association could par-
tially be due to an inadequate sample size, and being unpowered. Final-
ly, we found that CKD was an independent predictor for a higher risk of
all cause death, consistent with prior studies (Apostolakis et al., 2013;
Banerjee et al., 2014; Olesen et al., 2012). Importantly, the high risk
for death in our study was independently related to CKD and inversely
to effective anticoagulation (TTR N 70%).
Our data strengthen and reinforce the relationship between renal
function and TTR (Kleinow et al., 2011; Kooiman et al., 2014). One
study derived froma cohort of anticoagulated AFpatients found that pa-
tients withmoderate and severe CKD had higher TTR than patientswith
normal renal function, although CKD patients spent more time above
therapeutic range and INR-variability significantly increased in patients
with moderate and severe CKD (Kooiman et al., 2014). Recently, an
analysis from the Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation (ORBIT-AF) registry found that an estimated glomeru-
lar filtration rate below 60 ml/min/1.73 m2 was significantly associated
with a reduced TTR (≤53%) (Pokorney et al., 2015). Our results strongly
reinforce this relationship between renal function and anticoagulation
control, and that CKD patients derived benefit from VKA treatment
with good TTRs (Bonde et al., 2014).
Good quality anticoagulation control (TTR N 70%) was an indepen-
dent predictor for a lower risk of stroke, death and major bleeding.
There was a significant inverse correlation between TTR and HR risk
function for stroke, death and major bleeding overall, but when this
analysis was repeated in the CKD subgroup, the degree of correlation
was reduced for stroke and death risk, perhaps reflecting how CKD
modulates the risk of adverse events.
4.1. Limitations
Renal function data was only available based on the Cockroft-Gault
formula and not by more recent and validated methods of eGFR evalu-
ation (Levey et al., 2015). The original trial protocol excluded patients
with a severe CKD, and this may have led to an underestimate in the
prevalence of CKD in AF population. Also, the absence of subjects with
severe CKD precluded a more detailed analysis of the wider spectrum
of renal function and its influence on TTR and clinical outcomes. More-
over, other parameters used to evaluate anticoagulation control (e.g.
time spent below or above the target, proportion of INRs in range,
etc.) were not available for this analysis. Since the original trials were
run between 2000 and 2002, current clinical practice in managing AF
patients could have changed, with possible implications for the general-
izability of our results. However, VKAs are still very widely used world-
wide for thromboprophylaxis, in particular for treating AF patients with
CKD (Potpara et al., 2015). Thus, the association between CKD and TTRPlease cite this article as: Proietti, M., et al., Chronic Kidney Disease, Time i
Patients with Non-valvular Atria..., EBioMedicine (2016), http://dx.doi.orgremains relevant during the decision-making process to prescribe the
right drug for the right patient (Shields and Lip, 2015). Finally, the asso-
ciation of CKD with paroxysmal AF could be spurious, since only a low
proportion of these subjects were enrolled in the original trial cohort.
In conclusion, CKD is highly prevalent amongst AF patients and as-
sociated with several clinical comorbidities. Importantly, CKD in AF pa-
tients is an independent risk factor for stroke and death, but not major
bleeding after adjustment for TTR. Even after adjusting for CKD, good
quality anticoagulation control (TTR N 70%)was an independent predic-
tor for a lower risk of stroke, death and major bleeding.
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